Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis-Reference-Cited by-同舟云学术

Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis

Published:2019-02-28 Issue:4 Volume:34 Page:423-433
ISSN:0733-2459
Container-title:Journal of Clinical Apheresis
language:en
Short-container-title:J Clin Apher

Author:

Spitthöver Ralf¹,Röseler Tilmann²,Julius Ulrich³,Heigl Franz⁴,Schettler Volker J. J.⁵,Kühn Ralf⁶,Leebmann Josef⁷,Raabe Andrea⁸,Knittel Markus⁹,Schürfeld Carsten¹⁰,Moesenthin Michael⁶,Bernhardt Wanja M.²,Röseler Eberhard²,Ketteler Markus⁸,Heibges Andreas¹¹,Klingel Reinhard¹¹¹²^ORCID

Affiliation:

1. Dialysis and Lipid Center North Rhine; Essen Germany

2. Center for Nephrology; Hypertension, and Metabolic Diseases; Hannover Germany

3. 3 Medical Clinic; University Hospital at the Technische Universität; Dresden Germany

4. Medical Health and Care Center Kempten-Allgäu; Kempten Germany

5. Center for Nephrology; Göttingen Germany

6. Clinic for Nephrology and Dialysis; Tangermünde Germany

7. Interdisciplinary Apheresis Center at Passau General Hospital; Passau Germany

8. Clinic for Nephrology; General Hospital; Coburg Germany

9. Center for Dialysis and Apheresis; Witten Germany

10. Center for Nephrology and Dialysis; Saarlouis Germany

11. Apheresis Research Institute; Cologne Germany

12. First Department of Internal Medicine; University of Mainz; Mainz Germany

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jca.21695/fullpdf

Reference35 articles.

1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017

2. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease;Nordestgaard;Eur Heart J,2013

3. Defining severe familial hypercholesterolemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel;Santos;Lancet Diabetes Endocrinol,2016

4. Ezetimibe added to statin therapy after acute coronary syndromes;Cannon;N Engl J Med,2015

5. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pleiotropic effects of double filtration plasmapheresis;Therapeutic Apheresis and Dialysis;2024-09-08

2. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study;Journal of Cardiovascular Medicine;2023-09-29

3. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue;Journal of Clinical Apheresis;2023-04

4. The German Lipoprotein Apheresis Registry—Summary of the ninth annual report;Therapeutic Apheresis and Dialysis;2022-12

5. Beyond cholesterol—pleiotropic effects of lipoprotein apheresis;Therapeutic Apheresis and Dialysis;2022-12